Combining Semaglutide with Anti-Amyloid Treatments for Alzheimer's Disease
Combination Therapy with Semaglutide and Anti-Amyloid Antibodies for Alzheimers Disease
This study is looking at whether taking semaglutide, a medication for diabetes and weight loss, along with special antibodies can help improve thinking and memory for people with early-stage Alzheimer's disease, while also making treatment safer and more effective.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11015826 on NIH RePORTER |
What this research studies
This research investigates the effects of combining semaglutide, a medication typically used for diabetes and obesity, with anti-amyloid antibodies to improve treatment outcomes for early-stage Alzheimer's disease. The approach aims to enhance cognitive function while minimizing side effects associated with current anti-amyloid therapies. By leveraging semaglutide's neuroprotective and anti-inflammatory properties, the study seeks to address the limitations of existing treatments and improve patient safety. Participants may receive a combination of these therapies to evaluate their effectiveness in slowing cognitive decline.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with early-stage Alzheimer's disease who may also have conditions like Type 2 diabetes or obesity.
Not a fit: Patients with advanced Alzheimer's disease or those who do not have the ApoE4 genetic variant may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with early-stage Alzheimer's disease.
How similar studies have performed: Previous studies have shown promising results with GLP-1 receptor agonists in Alzheimer's models, indicating potential for success with this combined approach.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Lemere, Cynthia a — Brigham and Women's Hospital
- Study coordinator: Lemere, Cynthia a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.